Bergasa N V, Alling D W, Talbot T L, Swain M G, Yurdaydin C, Turner M L, Schmitt J M, Walker E C, Jones E A
National Institutes of Health, Bethesda, Maryland, USA.
Ann Intern Med. 1995 Aug 1;123(3):161-7. doi: 10.7326/0003-4819-123-3-199508010-00001.
To determine whether endogenous opioids contribute to the pruritus of cholestasis by studying the effect of the opiate antagonist naloxone on the perception of pruritus and on scratching activity in patients with this form of pruritus.
Double-blind, placebo-controlled, crossover trial with four periods.
Clinical research referral center.
29 pruritic patients with liver diseases of various causes.
Each patient received as many as two naloxone and two placebo solution infusions consecutively in random order. Each infusion lasted 24 hours.
During the infusions, visual analog scores of pruritus were recorded every 4 hours while patients were awake; scratching activity independent of limb movements was recorded continuously.
One patient had a mild reaction consistent with a naloxone-precipitated syndrome similar to opiate withdrawal. A significant 24-hour rhythm of scratching activity was seen in 7 of 11 patients for whom complete 96-hour data were collected. The mean of a visual analog score of the perception of pruritus (maximum, 10.0) recorded during naloxone infusions was 0.582 lower than that recorded during placebo infusions (95% CI, 0.176 to 0.988; P < 0.01). Furthermore, the ratio of the geometric mean hourly scratching activity during naloxone infusions to that during placebo infusions was 0.727 (CI, 0.612 to 0.842; P < 0.001) and was greater than 1.0 in only five patients.
Naloxone administration is associated with amelioration of the perception of pruritus and reduction of scratching activity in cholestatic patients. Because of the opioid receptor specificity of the action of naloxone, these findings support the hypothesis that a mechanism underlying the pruritus of cholestasis is modulated by endogenous opioids and suggest that opiate antagonists may have a role in the management of this complication of cholestasis.
通过研究阿片类拮抗剂纳洛酮对胆汁淤积性瘙痒患者瘙痒感知及搔抓活动的影响,确定内源性阿片类物质是否导致胆汁淤积性瘙痒。
双盲、安慰剂对照、四期交叉试验。
临床研究转诊中心。
29例因各种原因患有肝病的瘙痒患者。
每位患者按随机顺序连续接受多达两次纳洛酮和两次安慰剂溶液输注。每次输注持续24小时。
输注期间,患者清醒时每4小时记录一次瘙痒视觉模拟评分;连续记录与肢体运动无关的搔抓活动。
1例患者出现轻度反应,与纳洛酮诱发的综合征(类似于阿片类戒断反应)相符。在收集了完整96小时数据的11例患者中,有7例出现了明显的24小时搔抓活动节律。纳洛酮输注期间记录的瘙痒感知视觉模拟评分(最大值为10.0)的平均值比安慰剂输注期间低(0. )582(95%可信区间,(0. )176至(0. )988;(P < 0.01))。此外,纳洛酮输注期间每小时搔抓活动几何平均数与安慰剂输注期间的比值为(0. )727(可信区间,(0. )612至(0. )842;(P < 0.001)),只有5例患者该比值大于1.0。
在胆汁淤积患者中,给予纳洛酮可改善瘙痒感知并减少搔抓活动。由于纳洛酮作用的阿片受体特异性,这些发现支持了胆汁淤积性瘙痒的潜在机制受内源性阿片类物质调节的假说,并提示阿片类拮抗剂可能在胆汁淤积这一并发症的治疗中发挥作用。